Skip header and navigation

Refine By

30 records – page 1 of 3.

Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies.

https://arctichealth.org/en/permalink/ahliterature24760
Source
Lancet. 1991 Aug 31;338(8766):535-8
Publication Type
Article
Date
Aug-31-1991
Author
R. Arriagada
L E Rutqvist
Author Affiliation
Institut Gustave-Roussy, Villejuif, France.
Source
Lancet. 1991 Aug 31;338(8766):535-8
Date
Aug-31-1991
Language
English
Publication Type
Article
Keywords
Adult
Aged
Analysis of Variance
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy - epidemiology - radiotherapy
Combined Modality Therapy
Comparative Study
Cyclophosphamide - therapeutic use
Drug Administration Schedule
Drug Evaluation
Female
Fluorouracil - therapeutic use
Humans
Incidence
Methotrexate - therapeutic use
Middle Aged
Neoplasms, Multiple Primary - prevention & control
Radiotherapy Dosage
Registries
Research Support, Non-U.S. Gov't
Sweden - epidemiology
Tamoxifen - administration & dosage - therapeutic use
Time Factors
Abstract
Adjuvant chemotherapy is increasingly being given to patients with early breast cancer. Long-term follow-up studies suggest a higher frequency of secondary tumours, especially leukaemias, among women receiving such cytotoxic drugs. We studied the frequency of new primary malignancies in 1113 patients with early breast cancer who had been included in a randomised trial to compare chemotherapy as an adjunct to primary surgery with adjuvant locoregional radiotherapy. The estimated rate of new primary malignancies at ten years was significantly lower (p less than 0.0003) in the chemotherapy group (1%) than in the radiotherapy group (6%). The corresponding rate among 1986 patients treated with surgery alone was 5%. Our findings suggest that adjuvant chemotherapy in early breast cancer may protect against the development of new primary tumours in the first ten years of follow-up.
Notes
Comment In: Lancet. 1991 Oct 5;338(8771):885-61681236
PubMed ID
1678800 View in PubMed
Less detail

[Adjuvant radio-chemotherapy is effective in the treatment of Dukes B and C rectal cancer: results of a randomized controlled Norwegian trial]

https://arctichealth.org/en/permalink/ahliterature21437
Source
Strahlenther Onkol. 1998 Sep;174(9):490-1
Publication Type
Article
Date
Sep-1998

Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.

https://arctichealth.org/en/permalink/ahliterature263156
Source
Radiother Oncol. 2014 Dec;113(3):352-8
Publication Type
Article
Date
Dec-2014
Author
Otilia Leon
Marianne Guren
Oskar Hagberg
Bengt Glimelius
Olav Dahl
Hanne Havsteen
Gisela Naucler
Christer Svensson
Kjell Magne Tveit
Anders Jakobsen
Per Pfeiffer
Eva Wanderås
Tor Ekman
Birgitta Lindh
Lise Balteskard
Gunilla Frykholm
Anders Johnsson
Source
Radiother Oncol. 2014 Dec;113(3):352-8
Date
Dec-2014
Language
English
Publication Type
Article
Keywords
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Anus Neoplasms - mortality - radiotherapy - therapy
Chemoradiotherapy - methods
Cisplatin - therapeutic use
Cohort Studies
Denmark - epidemiology
Female
Fluorouracil - therapeutic use
Humans
Lymphatic Metastasis
Male
Middle Aged
Mitomycin - therapeutic use
Neoplasm Recurrence, Local - mortality
Norway - epidemiology
Practice Guidelines as Topic
Sex Factors
Survival Analysis
Sweden - epidemiology
Treatment Outcome
Abstract
To evaluate treatment outcome in a large population-based cohort of patients with anal cancer treated according to Nordic guidelines.
Clinical data were collected on 1266 patients with anal squamous cell carcinoma diagnosed from 2000 to 2007 in Sweden, Norway and Denmark. 886 of the patients received radiotherapy 54-64Gy with or without chemotherapy (5-fluorouracil plus cisplatin or mitomycin) according to different protocols, stratified by tumor stage.
High age, male gender, large primary tumor, lymph node metastases, distant metastases, poor performance status, and non-inclusion into a protocol were all independent factors associated with worse outcome. Among patients treated according to any of the protocols, the 3-year recurrence-free survival ranged from 63% to 76%, with locoregional recurrences in 17% and distant metastases in 11% of patients. The highest rate of inguinal recurrence (11%) was seen in patients with small primary tumors, treated without inguinal irradiation.
Good treatment efficacy was obtained with Nordic, widely implemented, guidelines for treatment of anal cancer. Inguinal prophylactic irradiation should be recommended also for small primary tumors.
PubMed ID
25499203 View in PubMed
Less detail

Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003.

https://arctichealth.org/en/permalink/ahliterature167711
Source
Acta Oncol. 2006;45(6):736-42
Publication Type
Article
Date
2006
Author
Kauko Saarilahti
Päivi Arponen
Leila Vaalavirta
Mikko Tenhunen
Carl Blomqvist
Author Affiliation
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. kauko.saarilahti@hus.fi
Source
Acta Oncol. 2006;45(6):736-42
Date
2006
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Anus Neoplasms - drug therapy - radiotherapy
Female
Finland
Fluorouracil - therapeutic use
Follow-Up Studies
Humans
Male
Middle Aged
Mitomycin - therapeutic use
Radiotherapy - adverse effects - methods
Treatment Outcome
Abstract
The number of elderly patients with cancer is steadily increasing in developed countries and their treatment is a growing challenge for oncological departments. Anal cancer is the first tumour in which chemoradiotherapy with the intent of organ preservation has largely replaced surgery and is an interesting model of modern multimodal oncological treatment. At the Department of Oncology of the Helsinki University Central Hospital we have treated all patients irrespective of age following the same guidelines if there have been no specific contraindications on the basis of intercurrent diseases. The results suggest that the chemoradiotherapy protocol used in the treatment of anal cancer is reasonably well tolerated in elderly patients and the tumour control is comparable to those achieved in younger patients. After successful cancer therapy the life expectancy in these patients can be very long.
PubMed ID
16938817 View in PubMed
Less detail

Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy).

https://arctichealth.org/en/permalink/ahliterature21121
Source
Drugs Exp Clin Res. 1998;24(5-6):221-6
Publication Type
Article
Date
1998
Author
G V Bondar
A V Borota
Y I Yakovets
S E Zolotukhin
Author Affiliation
Donetsk Regional Anti-Cancer Center, Ukraine.
Source
Drugs Exp Clin Res. 1998;24(5-6):221-6
Date
1998
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alkaloids - therapeutic use
Antineoplastic Agents - therapeutic use
Combined Modality Therapy
Comparative Study
Female
Fluorouracil - therapeutic use
Humans
Male
Middle Aged
Rectal Neoplasms - therapy
X-Ray Therapy
Abstract
A total of 48 patients suffering from rectum cancer were included in this randomized study conducted at the Proctology Department of the Donetsk Regional Anti-Cancer Center. Patients in group I (24 patients) received an intensive course of high fractional X-ray therapy (cumulative dose up to 25 Gy) with direct protracted endolymphatic chemotherapy with 5-fluorouracil (5-FU) instilled in 600 mg/m2 each day before operation, up to a cumulative dose of 5 g. The 24 patients in group II were treated with Ukrain as monotherapy, 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention. Repeated Ukrain courses (100 mg/per course) were also given 6 months after surgical operation. In each ease preoperative treatment was followed by routine surgical operation. Prolongation morbi were found to have developed 14 months later in six patients in group I (25.0%), whereas in group II they were found only in two cases (8.3%). Comparative investigation of objective and subjective signs, analysis of results of instrument and X-ray data, as well as dynamic study of the histological structure of rectal tumors, indicate that Ukrain exerts a more potent malignotoxic and immunomodulating action than other types of anticancer treatment.
PubMed ID
10190078 View in PubMed
Less detail

Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer.

https://arctichealth.org/en/permalink/ahliterature22899
Source
Drugs Exp Clin Res. 1996;22(3-5):115-22
Publication Type
Article
Date
1996
Author
Y M Susak
V S Zemskov
O Y Yaremchuk
O B Kravchenco
I M Yatsyk
O B Korsh
Author Affiliation
Department of General Surgery, Ukrainian State Medical University, Kiev, Ukraine.
Source
Drugs Exp Clin Res. 1996;22(3-5):115-22
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - therapeutic use
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic Agents - therapeutic use
Biopsy
Colorectal Neoplasms - drug therapy - pathology - radiotherapy
Combined Modality Therapy
Comparative Study
Female
Fluorouracil - therapeutic use
Humans
Male
Middle Aged
X-Ray Therapy
Abstract
Ninety six colorectal carcinoma patients were included in a randomised study, 48 were treated with Ukrain monotherapy (15 with metastatic and 33 with nonmetastatic colorectal carcinoma) and 48 with 5-fluorouracil (5-FU) and X-ray therapy (the same randomised groups). The results of therapy including clinical, haematological, immunological and biochemical parameters show that Ukrain has favourable properties in the treatment of colon and rectal cancer as a monotherapy because of its malignotoxic and immunomodulating action. Objective response rate in the group of metastatic colorectal cancer treated by Ukrain was 40%. There was no registered tumour regression in the group treated by 5-FU. Operability is strongly facilitated by pretreatment with Ukrain. The survival rate (up to 21 months) in the Ukrain-treated patients with nonmetastatic colorectal cancer was 78.6% and 33.3% in a corresponding control group. Ukrain is a new effective drug in the therapy of colorectal cancer. It can be useful both for the therapy of metastatic colorectal cancer and for neoadjuvant therapy of nonmetastatic colorectal cancer.
PubMed ID
8899313 View in PubMed
Less detail

30 records – page 1 of 3.